Alexey V. Danilov, MD, PhD

Articles

Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies

February 28th 2024

Alexey Danilov, MD, PhD, discusses unmet needs in hematologic malignancies to be discussed at the Bridging the Gaps in Hematologic Malignancies meeting.

Dr Danilov on Using MRD Status to Predict Outcomes in Hematologic Malignancies

January 30th 2024

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

Dr Danilov on Addressing BTK Inhibitor Resistance in Relapsed/Refractory CLL and MCL

January 12th 2024

Alexey Danilov, MD, PhD, discusses how further research may address unmet needs in chronic lymphocytic leukemia or mantle cell lymphoma.

Lisocabtagene Maraleucel in R/R MCL: Primary Analysis Results from the MCL Cohort of the Single-Arm, Multicenter, Seamless Design TRANSCEND NHL 001 Study

December 5th 2023

Alexey Danilov, MD, PhD, reviews data from the TRANSCEND NHL 001 study investigating lisocabtagene maraleucel in patients with relapsed/refractory mantle cell lymphoma.

Dr Danilov on the Investigation of BTK Degraders in CLL

October 8th 2023

Alexey Danilov, MD, PhD, discusses the investigation of BTK degraders in the treatment of chronic lymphocytic leukemia.

Future Directions in the Treatment of Mantle Cell Lymphoma

August 3rd 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.

TRANSCEND FL: Phase 2 Study Results of Lisocabtagene Maraleucel in Patients With R/R Follicular Lymphoma

August 1st 2023

Alexey Danilov, MD, PhD, reviews data from the phase 2 TRANSCEND FL trial investigating lisocabtagene maraleucel and discusses the clinical implications of the results.

Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

July 28th 2023

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma

July 28th 2023

Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr Danilov on Treatment Considerations in High-Risk MCL

July 24th 2023

Alexey Danilov, MD, PhD, discusses considerations for varying treatment approaches in patients with high-risk mantle cell lymphoma.

Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

July 20th 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma

July 20th 2023

Experts explain the role of maintenance therapy in mantle cell lymphoma and how it impacts the risk of disease progression.

Dr Danilov on Questions Remaining Across the Treatment Landscape of MCL

July 17th 2023

Alexey Danilov, MD, PhD, discusses lingering questions that remain across the treatment landscape of mantle cell lymphoma.

Dr Danilov on Therapeutic Options After BTK Inhibitors in MCL

July 14th 2023

Alexey Danilov, MD, PhD, discusses treatment developments for patients with mantle cell lymphoma who have progressed on BTK inhibitors.

Lisocabtagene Maraleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Primary Analysis of TRANSCEND CLL 004

June 29th 2023

Alexey Danilov, MD, PhD, presents an analysis of data from the Phase 1 TRANSCEND CLL 004 study investigating lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.

Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

May 31st 2023

Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.

Overview of Mantle Cell Lymphoma

May 31st 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, provide an overview of mantle cell lymphoma, including prevalence and common risk factors.

BTK Degraders and Other Targets in Mantle Cell Lymphoma

February 28th 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

The Role of Bispecific Antibodies in Mantle Cell Lymphoma

February 21st 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Treating Patients With MCL Who Progress on BTK Inhibitors

February 21st 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.